November 18, 2022
Yoshindo said on November 16 that it has acquired the exclusive commercialization rights in Japan for the biosimilars referencing monoclonal antibodies Stelara (ustekinumab) and Pralia (denosumab) from India-based Biocon Biologics. The companies had inked the agreement for the biosimilars, both...read more